1
|
Govekar SR, Lakshman LP, Reddy V, Mani RS, Mahadevan A, Susarla SK, Desai A, Banda RKV, Vasanthapuram R. Syndrome Evaluation System for Simultaneous Detection of Pathogens Causing Acute Encephalitic Syndrome in India, Part-2: Validation Using Well Characterized Clinical Samples. Front Neurol 2019; 9:1193. [PMID: 30697188 PMCID: PMC6341057 DOI: 10.3389/fneur.2018.01193] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2018] [Accepted: 12/28/2018] [Indexed: 11/13/2022] Open
Abstract
Diagnosis of the aetiological agent in case of acute encephalitic syndrome (AES) continues to pose a challenge in clinical practice as a variety of pathogens are known to cause AES. Here, we report the validation of a Syndrome Evaluation System (SES) developed for simultaneous detection of multiple AES pathogens using a well characterized set of Cerebrospinal fluid (CSF) samples. The validation of the SES was carried out in two phases. In the first phase, the SES was validated using 51 CSF samples obtained from autopsy proven cases and 50 samples obtained from apparently healthy individuals undergoing spinal anesthesia for minor surgeries served as "controls." The SES detected etilogical agent in 48/51 (94.11 %) samples obtained from autopsy proven AES cases while all the 50 CSF samples obtained from "controls" were negative. In the second phase, the SES was validated using well characterized CSF samples obtained from AES patients fulfilling the WHO case definition of AES (Group I; n = 207) and samples that were collected from patients with non-infectious neurological disorder (Group II; n = 90). All the samples were tested using multiple conventional/serological assays and categorized into various groups. Amongst the AES cases fulfilling WHO case definition, the SES detected AES pathogens in 160/207 (77.29%) cases while conventional serological/molecular assays were able to detect AES pathogens only in 77/207 (37.1%) of cases. Further, in 12/83 CSF samples that were positive by SES and negative by conventional serological/molecular tests, the results were additionally confirmed by sequencing the PCR products to rule out non-specific amplification in the SES. In patients with non-infectious neurological disorders the SES detected latent viruses 12/90 CSF samples. These results indicate that the SES, apart being a rapid, sensitive, specific, and cost-effective method provides the major advantage of simultaneous detection of multiple pathogens using as single specimen of CSF.
Collapse
Affiliation(s)
- Sunil R Govekar
- Research and Development, XCyton Diagnostics Limited, Bangalore, India
| | - Latha P Lakshman
- Research and Development, XCyton Diagnostics Limited, Bangalore, India
| | - Vijayalakshmi Reddy
- Neuropathology, National Institute of Mental Health and Neurosciences, Bangalore, India.,Department of Neurovirology, National Institute of Mental Health and Neurosciences, Bangalore, India
| | - Reeta S Mani
- Neuropathology, National Institute of Mental Health and Neurosciences, Bangalore, India.,Department of Neurovirology, National Institute of Mental Health and Neurosciences, Bangalore, India
| | - Anita Mahadevan
- Neuropathology, National Institute of Mental Health and Neurosciences, Bangalore, India
| | - Shankar K Susarla
- Neuropathology, National Institute of Mental Health and Neurosciences, Bangalore, India
| | - Anita Desai
- Neuropathology, National Institute of Mental Health and Neurosciences, Bangalore, India.,Department of Neurovirology, National Institute of Mental Health and Neurosciences, Bangalore, India
| | | | - Ravi Vasanthapuram
- Neuropathology, National Institute of Mental Health and Neurosciences, Bangalore, India.,Department of Neurovirology, National Institute of Mental Health and Neurosciences, Bangalore, India
| |
Collapse
|
2
|
An infectious HHV-6B isolate from a healthy adult with chromosomally integrated virus and a reporter based relative viral titer assay. Virus Res 2013; 173:280-5. [DOI: 10.1016/j.virusres.2013.02.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2012] [Revised: 02/03/2013] [Accepted: 02/04/2013] [Indexed: 02/05/2023]
|
3
|
Loutfy SA, Fawzy M, El-Wakil M, Moneer MM. Presence of human herpes virus 6 (HHV6) in pediatric lymphomas: impact on clinical course and association with cytomegalovirus infection. Virol J 2010; 7:287. [PMID: 20979645 PMCID: PMC2988729 DOI: 10.1186/1743-422x-7-287] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2010] [Accepted: 10/27/2010] [Indexed: 11/10/2022] Open
Abstract
Background Activation of herpes virus 6 (HHV6) has seen in Hodgkin's and non-Hodgkin's Lymphoma (HL&NHL) as a result of lymphoma associated immunosuppression. Multiple studies have suggested an association between both HHV6 and cytomegalovirus CMV for development of CMV disease affecting the pathogenesis of lymphoma. Therefore, this study investigated the frequency of HHV6, its impact on clinical manifestations of lymphoma and its possible association with risk for development of CMV infection in pediatric lymphoma patients. Methods Presence of HHV6 DNA and CMV DNA was investigated by PCR assay in both WBC's and plasma samples from 50 patients diagnosed with HL or NHL. CMV antibody titer was also determined in sera obtained from each patient. Twenty apparently healthy siblings were used as a control group. Results In a study group of 50 patients diagnosed with HL or NHL, 23/50 (46%) were found to be positive for herpes virus DNA (HHV6 or CMV) in WBC's or plasma by PCR assay and this was significantly higher than its presence in the pediatric control group 2/20 (10%) (p = 0.005). Ten out of these 23 (43%) were found to have active CMV infection. Fifty six percent of patients with CMV infection were found among NHL cases with B- subtype. The presence of both herpes viruses DNA was significantly associated with more frequent episodes of febrile neutropenia (median 3 episodes), absolute neutrophil count (< 0.8), lymphocytes (< 0.5), and low hemoglobin level (< 9.1), (p < 0.05). Conclusion The presence of HHV6 can be considered as a predicting indicator of cellular immunosuppression preceding the onset of CMV infection which may result in a severe outcome among pediatric lymphoma patients.
Collapse
Affiliation(s)
- Samah A Loutfy
- Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Egypt.
| | | | | | | |
Collapse
|
4
|
Abstract
The onset of AIDS is characterized by the collapse of the immune system after a prolonged asymptomatic period. The mechanistic basis of this disease progression has remained obscure, hindering the development of effective therapies. Here I present a mechanism that underlies the deterioration of the immune system during HIV infection. The elevated turnover of lymphocytes throughout the asymptomatic period is postulated to result in the accumulation of deleterious mutations, which impairs immunological function, replicative ability and viability of lymphocytes. This mutational meltdown is proposed to occur throughout the hierarchy of lymphocyte progenitors, resulting in the deterioration of lymphocyte regeneration and an ensuing rise in viral loads. A mathematical model is used to illustrate this mechanism of progressive immunological deterioration. Mutation accumulation may explain not only the decline in CD4+T cells, but also the functional deterioration of CD4+T cells, CD8+T cells and B cells, and the exhaustion of lymphocyte regeneration.
Collapse
Affiliation(s)
- Alison P Galvani
- Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT 06520, USA.
| |
Collapse
|
5
|
Mori S, Sugahara K, Uemura A, Akamatsu N, Hirakata Y, Murata K, Hasegawa H, Yamada Y, Kamihira S. Usefulness of a comprehensive PCR-based assay for human herpes viral DNA in blood mononuclear cell samples. ACTA ACUST UNITED AC 2005; 11:163-70. [PMID: 16174601 DOI: 10.1532/lh96.05027] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Human herpes virus (HHV) is well known to reactivate in immunocompromised situations and plays an immunomodulatory role leading to indirect effects through viral replication to the host. The aim of this study was to determine the laboratory and clinical relevance of a comprehensive PCR-based assay for detecting eight HHVs, which are lymphotropic and cause disease in humans. Using 176 samples collected from 146 specimens of peripheral blood, 12 skin nodules, 11 lymph nodes and 7 others of patients who were suspected to have adult T cell leukemia (ATL), the PCR-based assay was validated to simultaneously detect one or more herpes viral DNA with two consensus primer sets. Although most samples were seropositive for either of the HHVs, only 50% of them were positive for either herpes viral DNA with EBV in 76%, HHV-6 in 14% and VZV in 9%. Furthermore, such a herpes viral DNA positive status was not always associated with clinical symptoms relating to the virus, implying active replication in the blood cells, but being asymptomatic. HHV-8 viral DNA, although Kaposi's sarcoma has been reported to be complicated with ATL, was not demonstrable. HHV-6B was detected only in HTLV-1 healthy carriers and ATL patients, and may imply a co-factor role with HTLV-1. This PCR-based assay provides a herpes viral infectious status compensatory for virus-serology and is a clinically relevant laboratory test, serving as a screening marker for active infection.
Collapse
Affiliation(s)
- Sayaka Mori
- Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, and Central Diagnostic, Laboratory, Nagasaki University Hospital, Nagasaki City, Nagasaki, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|